INTRODUCTION {#s1}
============

Glioma that arises from glial or precursor cells is one of the most common and aggressive malignant primary intracranial brain tumors. The incidence rate 6.02 per 100,000, particularly among adults \[[@R1]\]. Glioma accounts for approximately 30% of all brain and central nervous system tumors and 80% of all malignant brain tumors \[[@R2]\]. It is one of the primary causes of cancer-related deaths worldwide and of refractory cancer in the field of neurosurgery. Gliomas are classified as astrocytomas, oligodendrogliomas, oligoastrocytomas and glioblastomas based on cellular lineage. The World Health Organization (WHO) classifies gliomas into four clinical grades: I, pilocytic astrocytomas; II, diffuse low grade gliomas; III, anaplastic gliomas; and IV, glioblastoma \[[@R3]\].

Gliomas are characterized by extensive vasculature, rapid growth, and a short disease course. Because gliomas typically invade the perivascular spaces within the brain tissue resulting in irregular borders, they are difficult to completely resect surgically \[[@R4]\]. Therefore, patients have relatively high postoperative recurrence rates and short survival times. Despite significant improvement in glioma diagnostics and therapeutics (e.g., surgery, radiotherapy and chemotherapy), the prognosis of glioma patients is still dismal compared to patients with other types of brain tumors. For example, the median survival time (MST) of patients with glioblastoma ranges from 12 to 15 months and the majority of patients die within 2 years of diagnosis. At present, the precise etiology and pathogenic mechanisms underlying glioma development and progression are unknown.

Several clinical factors affect the prognosis of glioma patients. These include age; gender; preoperative symptoms; preoperative disease duration; preoperative Karnofsky Performance Status (KPS) score; tumor grade, size, range and location; and histological grade. There are also several factors related to treatment that can affect patient prognosis including the surgical method, extent of surgical resection, duration of surgery, radiotherapy and chemotherapy. Most gliomas result from the combined action of environmental factors and inherited genetic variations. Many studies have suggested that genetic polymorphisms in the epidermal growth factor receptor (*EGFR*) are associated with risk of glioma \[[@R5]--[@R7]\], breast cancer \[[@R8]\], colorectal adenoma and colorectal cancer \[[@R9]\], and non-small cell lung cancer \[[@R10]\].

The *EGFR* gene is located on chromosome 7p12-13 and encodes for a 170 kD transmembrane receptor tyrosine kinase that is expressed on the surface of epithelial cells \[[@R11]\]. What is more, it is the first receptor discovered to possess tyrosine kinase activity and to be sequenced. Previous have demonstrated that activation of the EGFR signaling pathway contributes to many biological processes including cell survival, proliferation, apoptosis, differentiation, cell cycle progression, invasion, metastasis and angiogenesis \[[@R12], [@R13]\], all of which are associated with tumor progression. EGFR signaling is initiated by ligand binding to the extracellular ligand-binding domain, which initiates receptor dimerization and tyrosine auto-phosphorylation, resulting in receptor activation \[[@R14]\]. Amplification and/or overexpression of *EGFR* have been observed in approximately 50% of malignant gliomas \[[@R15]\] compared to approximately 10 to 26% of anaplastic astrocytomas \[[@R16]\]. *EGFR* amplification was associated with worse outcomes in glioblastoma patients \[[@R17]\]. However, the exact pathogenesis and biological mechanisms by which polymorphisms in *EGFR* contribute to glioma development are unclear.

Although previous association studies demonstrated that genetic polymorphisms in *EGFR* were associated with glioma risk, few studies focused on the effects of these alterations on glioma patient prognosis. We hypothesized that SNPs in *EGFR* could impact the prognosis of glioma patient. To test this hypothesis, we screened and genotyped eight SNPs in *EGFR* and evaluated the associations between these SNPs and the prognosis of glioma patients in a Chinese population.

RESULTS {#s2}
=======

Patient characteristics and clinical data {#s2_1}
-----------------------------------------

A total of 269 glioma patients were analyzed in this study: 160 astrocytoma patients, 19 ependymoma, 9 oligodendroglioma, 31 oligodendrocyte astrocytoma, 42 glioblastoma and 8 with other types of glioma. The characteristics and detailed clinical data for the patients with glioma as well as 160 astrocytoma patients (WHO grade I--IIΙ) are summarized in Table [1](#T1){ref-type="table"}. Among 269 glioma patients, there were 145 (53.9%) men and 124 (46.1%) women. There were 116 patients \< 40 years of age and 153 ≥ 40 years of age. A total of 18 (6.7%) patients were classified as WHO grade I, 129 (48.0%) as WHO grade II, 72 (26.8%) as WHO grade III, and 50 (18.6%) as WHO grade IV. Gamma knife radiotherapy was administered to 176 (65.4%) patients and conformal radiation therapy was administered to 69 (25.7%) patients. Finally, 104/269 (38.7%) patients received chemotherapy. At the time of the last follow-up, 249 (92.6%) glioma patients had died. The results of the genotyping for the eight SNPs are shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.

###### Characteristics of glioma and astrocytoma subjects

  Variable              Classification   Glioma   Astrocytoma         
  --------------------- ---------------- -------- ------------- ----- -------
  Gender                Male             145      53.9%         88    55.0%
                        Female           124      46.1%         72    45.0%
  Age (years)           \< 40            116      43.1%         66    41.3%
                        ≥ 40             153      56.9%         94    58.8%
  WHO grade             WHO I            18       6.7%          18    11.3%
                        WHO II           129      48.0%         78    48.8%
                        WHO III          72       26.8%         64    40.0%
                        WHO IV           50       18.6%         \-    \-
  Extent of resection   GTR              184      68.4%         111   69.4%
                        STR or NTR       85       31.6%         49    30.6%
  Radiotherapy          GK               176      65.4%         106   66.3%
                        CRT              69       25.7%         41    25.6%
                        No               24       8.9%          13    8.1%
  Chemotherapy          Platinum         56       20.8%         37    23.1%
                        Nimustine        32       11.9%         14    8.8%
                        Temozolomide     16       5.9%          7     4.4%
                        No               165      61.3%         102   63.8%
  Survival condition    Survival         11       4.1%          6     3.8%
                        Lost             9        3.3%          7     4.4%
                        Death            249      92.6%         147   91.9%
  Progress              Yes              10       3.7%          6     3.8%
                        No               255      94.8%         152   95.0%
                        Missing system   4        1.5%          2     1.3%

WHO: World Health Organization; GTR: Gross-total resection; NTR: Near-total resection;

STR: Sub-total resection; GK: Gamma knife; CRT: Conformal radiation therapy.

Univariate analysis {#s2_2}
-------------------

Clinical factors including gender, age, WHO grade, extent of resection, radiotherapy and chemotherapy were assessed in a univariate analysis (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). We determined that age ≥ 40 was a hazardous factor with a 1.30-fold (Log-rank *p* = 0.025, hazard ratio \[HR\] = 1.302, 95% confidence interval \[CI\] = 1.010--1.678, *p* = 0.041) and 1.29-fold (Log-rank *p* = 0.025, HR = 1.290, 95% CI = 1.004--1.659, *p* = 0.047) increased risk of death on overall survival (OS) and progression-free survival (PFS) in glioma patients, respectively. The MSTs was 10 and 8 months, and the 3-year survival rates were 4.2% and 2.6% of the OS and PFS, respectively (Table [2](#T2){ref-type="table"}). In contrast, the extent of resection (gross-total resection) and chemotherapy were protective against mortality factors. Gross-total resection was associated with a 35.5% (Log-rank *p* = 0.000, HR = 0.645, 95% CI = 0.492--0.845, *p* = 0.001) and 38.6% (Log-rank *p* = 0.000, HR = 0.614, 95% CI = 0.468--0.806, *p* = 0.000) decrease in mortality hazard, the MSTs were 11and 8 months, 3-years survival rates were 8.9% and 4.9% of the OS and PFS in glioma patients, respectively. Treatment with chemotherapy was also associated with a reduced risk of death measured by OS and PFS in glioma patients (Log-rank *p* =0.001, HR = 0.660, 95% CI = 0.506--0.860, *p* = 0.002; Log-rank *p* = 0.019, HR = 0.755, 95% CI = 0.580--0.984, *p* = 0.038, respectively) (Table [2](#T2){ref-type="table"}). The gross-total resection and chemotherapy were also positive factors in astrocytoma patients with OS (Log-rank *p* = 0.003, HR = 0.614, 95% CI = 0.431--0.875, *p* = 0.007; Log-rank *p* = 0.020, HR = 0.705, 95% CI = 0.498--0.997, *p* = 0.048, respectively), and the MSTs were11and12 months respectively. Gross-total resection was associated with the PFS in astrocytoma patients (Log-rank *p* = 0.000, HR = 0.556, 95% CI = 0.389--0.794, *p* = 0.001), with an 8 month MST (Table [3](#T3){ref-type="table"}). nNo significant correlations were identified between gender, WHO grade, or radiotherapy and prognosis the of glioma and astrocytoma patients as measured by OS and PFS.

###### Univariate analysis of the impact of clinical factors on glioma patient OS and PFS

  Variable              Classification   OS         PFS                                                                                                                                              
  --------------------- ---------------- ---------- ----------- ------- -------------------- -------------------- --------- ---------- ----------- ------- -------------------- -------------------- -------
  Gender                Male             145/135    25.5/5.3    11                           1                              143/138    16.1/3.5    8                            1                    
                        Female           124/114    35.5/7.9    11      0.522                0.928(0.723-1.192)   0.559     122/117    15.6/4.1    8       0.579                0.940(0.734-1.203)   0.622
  Age(years)            \<40             116/103    36.2/9.5    12                           1                              113/107    20.4/5.3    8                            1                    
                        ≥40              153/146    25.5/4.2    10      0.025                1.302(1.010-1.678)   0.041     152/148    12.5/2.6    8       0.025                1.290(1.004-1.659)   0.047
  WHO grade             I-II             147/133    32.0/8.6    12                           1                              145/139    16.6/4.1    8                            1                    
                        III-IV           122/116    27.9/4.6    10      0.127                1.194(0.930-1.532)   0.164     120/116    15.0/3.3    8       0.245                1.139(0.890-1.458)   0.302
  Extent of resection   STR or NTR       85/84      17.6/1.2    10                           1                              82/81      12.0/−      8                            1                    
  GTR                   184/165          35.9/8.9   11          0.000   0.645(0.492-0.845)   0.001                183/174   22.4/4.9   8           0.000   0.614(0.468-0.806)   0.000                
  Radiotherapy          No               24/22      33.3/8.3    8                            1                              21/21      9.5/−       6                            1                    
                        CRT              69/60      20.3/11.8   9                            0.856(0.523-1.402)   0.536     68/61      16.2/10.3   7                            1.060(0.641-1.752)   0.821
                        GK               176/167    33.5/5.2    11      0.681                0.834(0.534-1.303)   0.426     176/173    16.5/1.7    8       0.834                0.976(0.619-1.539)   0.918
  Chemotherapy          No               165/158    24.1/2.7    9                            1                              164/164    15.9/−      7                            1                    
                        Yes              104/91     39.4/12.7   12      0.001                0.660(0.506-0.860)   0.002     101/91     15.8/9.9    8       0.019                0.755(0.580-0.984)   0.038

OS: Overall survival; PFS: Progression free survival; WHO: World Health Organization; GTR: Gross-total resection; NTR: Near-total resection;

STR: Sub-total resection; CRT: Conformal radiation therapy; GK: Gamma knife; SR: Survival rate; MST: Median survival time (months)

HR: Hazard ratio; 95% CI: 95% Confidence interval

Log-rank *p* values were calculated from Chi-Square test

*p* values were calculated from Wald test

*p* \< 0.05 indicates statistical significance

###### Univariate analysis of the impact of clinical factors on astrocytoma patient OS and PFS

  Variable              Classification   OS         PFS                                                                                                                                              
  --------------------- ---------------- ---------- ----------- ------- -------------------- -------------------- --------- ---------- ----------- ------- -------------------- -------------------- -------
  Gender                Male             88/80      26.1/6.8    11                           1                              87/84      18.4/3.4    8                            1                    
                        Female           72/67      31.9/6.3    11      0.769                1.045(0.755-1.447)   0.789     71/68      11.3/4.2    8       0.629                1.072(0.778-1.478)   0.669
  Age(years)            \<40             66/58      31.8/8.6    11                           1                              65/62      16.9/4.6    8                            1                    
                        ≥ 40             94/89      26.6/3.2    10      0.184                1.227(0.880-1.711)   0.227     93/90      14.0/3.2    8       0.140                1.243(0.896-1.723)   0.192
  WHO grade             I-II             96/86      28.1/4.2    11                           1                              95/91      14.7/4.2    8                            1                    
                        III              64/61      29.7/3.9    11      0.612                1.081(0.778-1.501)   0.643     63/61      15.9/3.2    8       0.959                1.008(0.728-1.394)   0.964
  Extent of resection   STR or NTR       49/49      16.3/−      9                            1                              48/48      0/−         7                            1                    
  GTR                   111/98           34.2/9.6   11          0.003   0.614(0.431-0.875)   0.007                110/104   21.8/5.5   8           0.000   0.556(0.389-0.794)   0.001                
  Radiotherapy          No               13/11      46.2/−      12                           1                              14/11      18.2/−      11                           1                    
                        CRT              41/37      14.6/8.8    9                            1.475(0.749-2.905)   0.261     41/38      12.2/7.3    7                            1.700(0.861-3.355)   0.126
                        GK               106/99     32.1/2.8    11      0.334                1.183(0.634-2.209)   0.598     106/103    16.0/2.8    8       0.163                1.326(0.709-2.480)   0.376
  Chemotherapy          No               102/96     23.5/−      9                            1                              101/101    15.8/−      7                            1                    
                        Yes              58/51      37.9/11.4   12      0.029                0.705(0.498-0.997)   0.048     57/51      14.0/10.5   8       0.137                0.794(0.562-1.119)   0.187

OS: Overall survival; PFS: Progression free survival; WHO: World Health Organization; GTR: Gross-total resection; NTR: Near-total resection;

STR: Sub-total resection; CRT: Conformal radiation therapy; GK: Gamma knife; SR: Survival rate; MST: Median survival time(months)

HR: Hazard ratio; 95% CI: 95% Confidence interval

Log-rank *p* values were calculated using the Chi-Square test

*p* values were calculated using the Wald test

*p* \< 0.05 indicates statistical significance

According to Log-rank tests and Cox regression analysis, four of the eight SNPs evaluated in *EGFR* showed statistically significantly correlations with OS and PFS (Table [4](#T4){ref-type="table"}). Kaplan-Meier curves of OS and PFS for the different genotypes of the four SNPs are shown in Figure [1A--1H](#F1){ref-type="fig"}. Interestingly, the G/G genotype of rs11506105 was correlated with poor prognosis in glioma patients as measured by OS and PFS (HR = 1.687, 95% CI = 1.156--2.462, *p* = 0.007; HR = 1.594, 95% CI = 1.087--2.337, *p* = 0.017, respectively). Similar results were observed for the C/C genotype of rs3752651, which was significantly associated with increased OS and PFS (HR = 5.725, 95% CI = 1.390--23.584, *p* = 0.016; HR = 5.445, 95% CI = 1.325--22.372, *p* = 0.019, respectively), relative to the T/T genotypes. The C/C genotype ofrs1468727 had a negative effect on OS and PFS compared to the common T/T genotype, (HR = 1.564, 95% CI = 1.103--2.218, *p* = 0.012; HR = 1.497, 95% CI = 1.057--2.120, *p* = 0.023, respectively). Furthermore, the A/A genotype of rs845552 was inversely correlated with OS (HR = 1.636, 95% CI = 1.144--2.339, *p* = 0.007) and PFS (HR = 1.628, 95% CI = 1.137--2.330, *p* = 0.008) in glioma patients. No significant associations were identified between the eight EGFR SNPs analyzed and OS or PFS in astrocytoma patients.

![Kaplan-Meier curves for OS and PFS for patients with different genotypes corresponding to four *EGFR* SNPs (rs11506105, rs3752651, rs1468727 and rs845552)](oncotarget-07-63054-g001){#F1}

###### Univariate analysis of the association between eight SNPs in *EGFR* and glioma patient OS and PFS

  SNP-ID       Region      Genotype   OS         PFS                                                                                                                     
  ------------ ----------- ---------- ---------- ----------- ------- ------- --------------------- --------- ---------- ---------- ------- ------- --------------------- -------
  rs17172432   Intron 1    T/T        222/206    30.6/6.1    11      0.661   1                               219/211    16.4/3.7   8       0.738   1                     
                           C/T        45/41      28.9/5.7    10              1.030(0.736-1.440)    0.864     44/42      13.6/4.5   8               0.992(0.712-1.382)    0.963
                           C/C        2/2        \-          9               1.817(0.449-7.354)    0.403     2/2        \-         6               1.655(0.410-6.685)    0.480
  rs4947492    Intron 1    A/A        108/98     32.4/6.5    11      0.402   1                               108/104    16.7/3.7   8       0.481   1                     
                           G/A        132/122    43.9/6.8    11              1.049(0.804-1.369)    0.725     129/123    16.3/4.7   8               0.980(0.755-1.273)    0.882
  rs12718945               G/G        29/29      24.1/−      10              1.298(0.856-1.967)    0.220     28/28      10.7/−     7               1.227(0.807-1.868)    0.339
  Intron 1     G/G         109/99     33.0/6.4   12          0.395   1                             109/105   16.5/3.7   8          0.474   1                             
                           G/T        128/118    28.9/7.0    11              1.050(0.804-1.372)    0.720     125/119    16.8/4.8   8               0.983(0.756-1.278)    0.896
                           T/T        29/29      24.1/−      10              1.300(0.858-1.970)    0.215     28/28      10.7/−     7               1.233(0.811-1.876)    0.327
  rs730437     Intron 4    A/A        87/77      36.8/8.2    12      0.051   1                               85/81      20.0/4.7   8       0.145   1                     
                           C/A        136/127    27.9/5.6    11              1.113(0.838-1.479)    0.459     136/131    14.7/3.7   8               1.090(0.825-1.440)    0.543
                           C/C        46/45      23.9/2.2    9               1.513(1.045-2.190)    0.028     44/43      11.4/2.3   7               1.390(0.958-2.017)    0.083
  rs11506105   Boundary    A/A        95/83      36.8/9.6    12      0.011   1                               93/88      21.5/5.4   8       0.026   1                     
                           A/G        131/123    27.5/5.4    11              1.143(0.864-1.512)    0.348     131/126    14.5/3.8   8               1.112(0.846-1.462)    0.448
                           G/G        41/41      22.0/−      9               1.687(1.156-2.462)    0.007     39/39      7.7/−      7               1.594(1.087-2.337)    0.017
  rs3752651    Intron 13   T/T        224/207    29.9/6.3    11      0.020   1                               222/213    16.7/4.1   8       0.024   1                     
                           C/T        42/39      31.0/4.1    10              1.039(0.738-1.463)    0.826     40/39      12.5/2.5   8               1.033(0.734-1.454)    0.851
                           C/C        2/2        0/−         6               5.725(1.390-23.584)   0.016     2/2        \-         4               5.445(1.325-22.372)   0.019
  rs1468727    Intron 13   T/T        71/63      35.2/8.6    12      0.008   1                               71/67      21.1/5.6   8       0.019   1                     
                           T/C        130/119    31.5/8.4    11              1.062(0.783-1.443)    0.698     128/123    17.2/3.9   8               1.066(0.791-1.436)    0.676
                           C/C        66/66      21.2/0      10              1.564(1.103-2.218)    0.012     64/64      6.3/−      7               1.497(1.057-2.120)    0.023
  rs845552     Intron 19   G/G        97/84      37.1/10.5   12      0.009   1                               95/89      25.3/6.3   8       0.009   1                     
                           G/A        122/115    25.4/5.8    10              1.307(0.985-1.734)    0.064     121/117    12.4/3.3   8               1.279(0.968-1.689)    0.083
                           A/A        49/49      26.5/−      10              1.636(1.144-2.339)    0.007     48/48      6.3/−      7               1.628(1.137-2.330)    0.008

SR: Survival rate; MST: Median survival time(months)

HR: Hazard ratio; 95% CI: 95% Confidence interval

Log-rank *p* values were calculated using the Chi-Square test

*p* values were calculated using the Wald test

*p* \< 0.05 indicates statistical significance

Multivariate analysis {#s2_3}
---------------------

After adjusting for the various clinical factors, multivariate Cox regression analysis demonstrated that the SNP genotype was an independent prognostic factor for OS and PFS. We identified significant correlations between five SNPs in *EGFR* (rs11506105, rs3752651, rs1468727, rs845552 and rs730437) and the prognosis of glioma patients (Table [5](#T5){ref-type="table"}). The G/G genotype of rs11506105 was correlated with worse OS and PFS in glioma patients (adjusted HR = 1.680, 95% CI = 1.145--2.466, *p* = 0.008; adjusted HR = 1.542, 95% CI = 1.047--2.272, *p* = 0.028, respectively). Moreover, the C/C genotype of rs3752651 was prominently associated with a 5.313-fold (adjusted HR = 5.313, 95% CI = 1.279--22.074, *p* = 0.022) and 5.847-fold (adjusted HR = 5.847, 95% CI = 1.414--24.179, *p* = 0.015) risk of death as measured by OS and PFS, respectively. A very similar trend was observed for the C/C genotype of rs1468727, which had a significant impact on OS and PFS (adjusted HR = 1.650, 95% CI = 1.158--2.351, *p* = 0.006; adjusted HR = 1.487, 95% CI = 1.049--2.108, *p* = 0.026, respectively). In comparison to those patients with the genotype G/G of rs845552, the genotype A/A was associated with an increase in mortality hazard of borderline statistical significance as measured by OS and PFS (adjusted HR = 1.614, 95% CI = 1.127--2.312, *p* = 0.009; adjusted HR = 1.580, 95% CI = 1.104--2.270, *p* = 0.013, respectively). In addition, we found that the C/C genotype of rs730437 was associated with reduced OS compared to the A/A genotype (adjusted HR = 1.513, 95% CI = 1.041--2.201, *p* = 0.030). However, we did not identify an association between theses SNPs in *EGFR* and either OS and PFS in astrocytoma patients.

###### Multivariate analysis of the associations between eight SNPs in *EGFR* and glioma patient OS and PFS

  SNP-ID       Genotype   OS                      PFS                             
  ------------ ---------- ----------------------- ------- ----------------------- -------
  rs17172432   T/T        1                       0.512   1                       0.729
               C/T        1.121 (0.799--1.571)    0.508   1.018 (0.730--1.418)    0.918
               C/C        2.020 (0.495--8.240)    0.327   1.764 (0.433--7.180)    0.428
  rs4947492    A/A        1                       0.494   1                       0.574
               G/A        1.053 (0.806--1.376)    0.706   0.990 (0.762--1.287)    0.941
               G/G        1.287 (0.848--1.952)    0.235   1.230 (0.808--1.873)    0.335
  rs12718945   G/G        1                       0.471   1                       0.575
               G/T        1.073 (0.820--1.404)    0.606   1.004 (0.771--1.306)    0.978
               T/T        1.297 (0.855--1.965)    0.221   1.239 (0.814--1.886)    0.316
  rs730437     A/A        1                       0.094   1                       0.257
               C/A        1.139 (0.857--1.514)    0.370   1.121 (0.849--1.482)    0.421
               C/C        1.513 (1.041--2.201)    0.030   1.373 (0.942--2.002)    0.100
  rs11506105   A/A        1                       0.029   1                       0.090
               A/G        1.161 (0.877--1.536)    0.297   1.123 (0.854--1.477)    0.406
               G/G        1.680 (1.145--2.466)    0.008   1.542 (1.047--2.272)    0.028
  rs3752651    T/T        1                       0.064   1                       0.051
               C/T        1.101 (0.780--1.554)    0.583   1.037 (0.737--1.460)    0.835
               C/C        5.313 (1.279--22.074)   0.022   5.847 (1.414--24.179)   0.015
  rs1468727    T/T        1                       0.005   1                       0.041
               T/C        1.024 (0.753--1.392)    0.879   1.037 (0.769--1.398)    0.813
               C/C        1.650 (1.158--2.351)    0.006   1.487 (1.049--2.108)    0.026
  rs845552     G/G        1                       0.027   1                       0.039
               G/A        1.297 (0.976--1.724)    0.073   1.253 (0.948--1.656)    0.113
               A/A        1.614 (1.127--2.312)    0.009   1.583 (1.104--2.270)    0.013

OS: Overall survival; PFS: Progression free survival.

HR: Hazard ratio; 95% CI: 95% Confidence interval.

*p* values were calculated using the Wald test.

*p* \< 0.05 indicates statistical significance.

DISCUSSION {#s3}
==========

In this study, we examined the associations between eight different SNPs in *EGFR* and prognosis of a population of Chinese glioma patients. Our data indicated that age, extent of resection, chemotherapy and five SNPs (rs11506105, rs3752651, rs1468727, rs845552 and rs730437) impacted the survival of glioma patients. In contrast, no significant associations were identified between the eight SNPs in *EGFR* and the prognosis of astrocytoma patients.

Consistent with previous studies, age \[[@R18], [@R19]\], the extent of resection \[[@R20]\] and chemotherapy \[[@R21]\] were found to be key prognostic factors in glioma patients survival. But not all previous studies, Durmaz, et al. showed that the extent of resection had no significant influence on the survival times of patients with low grade glioma \[[@R22]\]. It is likely that the differing conclusions resulted from the diverse ages and ethnicities of the patients included in the studies, and pathological differences in glioma grade. Although in this study we did not find that WHO grade and radiotherapy were associated glioma patient prognosis, the median OS of the WHO grade I--II glioma patients was longer than that of WHO grade III--IV patients (12 months and 10 months, respectively). These results suggested that WHO grade did have some effect on glioma patient prognosis. It is likely that the samples we collected had some variability. We will therefore verify the results using a larger sample size in future studies., Keime-Guibert et al. simultaneously found that postoperative radiotherapy improved postoperative survival time in elderly patients with high-grade gliomas \[[@R23]\]. This could be explained by the fact that we only analyzed the impact of radiotherapy on glioma patient prognosis and did not perform a comprehensive stratification analysis.

In addition to research focused on the molecular mechanisms underlying glioma development, there is increasing interest in the identification of tumor-related biomarkers. Interestingly, the EGFR gene is the most frequently amplified gene in glioblastoma, and it is a strong prognostic indicator in glioma. Additionally, EGFR-mediated signaling pathways confer growth and survival advantages to tumor cells, promoting a state of continuous and unregulated proliferation. This ultimately results in expansion of the number of malignant cells and a rapid increases in tumor size \[[@R24]\]. Previous studies have shown that EGFR polymorphisms are associated with patient prognosis in a variety of cancers such as head and neck cancer \[[@R25]\], lung cancer \[[@R26]\], colorectal carcinoma \[[@R27]\], breast cancer \[[@R28]\], bladder cancer \[[@R29]\] and esophageal cancer \[[@R30]\]. However, the prognostic value of *EGFR* polymorphisms is not entirely clear. While EGFR amplification and overexpression were previously reported to impact the prognosis of glioma patients, the conclusions of the studies were inconsistent \[[@R31]--[@R33]\]. Several clinical and histopathological studies reported that amplification and overexpression of EGFR was associated with a shorter interval to relapse and poor survival in glioblastoma patients \[[@R33]--[@R35]\], low-grade glioma patients \[[@R36]\] and anaplastic astrocytoma patients \[[@R22], [@R32]\]. Nevertheless, in a small study of 107 glioblastoma patients, *EGFR* amplification was not found to be a significant prognostic indicator of OS \[[@R37]\]. The same results were seen in a larger study of 715 glioblastoma patients \[[@R38]\]while the results of another study was inconclusive \[[@R31]\]. Differences in the experimental approaches, sample size, ethnicity of the patient populations or geographic areas may explain the inconsistent results.

Our data indicated that the range of survival times for glioma patients with the C/C genotype of rs3752651 and rs1468727, the G/G genotype of rs11506105 and the A/A genotype of rs845552 were much shorter. It is possible that these SNPs are associated with increased receptor activation, *EGFR* expression or stability, which could increase cancer risk by promoting cell proliferation. Interestingly, one study showed that the G/G genotype of rs845552 was associated with increased survival rin Hispanic and non-Hispanic white breast cancer patients, but no anything association between rs3752651 and the prognosis of breast cancer patients was observed \[[@R8]\]. Similarly, rs3752651 was not significantly associated with non-small cell lung cancer survival in a Chinese population \[[@R10]\]. The prognostic significance of rs4947492 on OS was demonstrated in advanced lung adenocarcinoma patients treated with Gefitinib \[[@R39]\]. However, no significant associations between rs4947492 and glioma patient survival was observed in the current study. This may be explained by the fact that different genetic variants in *EGFR* could have different functional properties that influence prognosis in various cancers. In addition, rs1468727 is located at the intron region indicating it is not likely to affect protein function. The rational explanation may be that these SNPs have a tight linkage with other functional SNPs. While we failed to detect an association between rs730437 and patient prognosis in the univariate survival analysis, multivariate analysis showed that the C/C genotype of rs730437 negatively affected on OS in glioma patients. However, a previous report indicated that the C/C genotype of rs730437 was associated with longer survival time in patients with glioblastoma in the Swedish and Danish \[[@R15]\]. This inconsistency may be explained differences in patient ethnicity. No studies have been published on the complete genetic variance of *EGFR* and glioblastoma prognosis. Thus, future studies of the functions of SNPs in *EGFR* are warranted in order to fully understand their effects on the prognosis of patient with glioma. A previous study found that rs17172432, rs4947492 and rs12718945 were associated with a decreased risk of glioblastoma in a European population \[[@R5]\]. However, the three SNPs were not correlated with the risk of glioma in a Han Chinese population \[[@R6]\]. They had no influence on the prognosis of glioma patients in the present study. Collectively, these data indicate that the three SNPs may have different prognostic effects on glioma patients with differing ethnicities.

It is worth mentioning that there were several inherent limitations in our study. First, the patient cohort included only the Chinese population and the sample size was relatively small. Therefore, our results should be validated in larger patient cohorts consisting of patients from other ethnic groups and geographic areas. Additionally, we could not collect complete and comprehensive information on the clinical pathologic characteristics of the patients. Our data demonstrated that age, extent of resection and chemotherapy are associated with OS and PFS. Finally, the details of the mechanisms underlying the observed associations were beyond the scope of this study. Future studies with more precise clinicopathological data as well as functional studies are required to investigate the role of *EGFR* polymorphisms on glioma patient outcomes. Despite these limitations, the significant association between *EGFR* polymorphisms and prognosis in patients with glioma warrants has demonstrated its potential as a promising therapeutic target in glioma.

In conclusion, our data indicated that age, extent of resection, chemotherapy and five different SNPs (rs11506105, rs3752651, rs1468727 rs845552 and rs730437) in *EGFR* were associated with the prognosis of glioma patients. However, no prominent correlations were observed between the eight SNPs in *EGFR* and the prognosis of astrocytoma patients. Additional studies based on larger sample sizes and patients with different ethnicities are needed to further evaluate the association between genetic polymorphisms in *EGFR* and the prognosis of glioma and astrocytoma patients in larger samples.

MATERIALS AND METHODS {#s4}
=====================

Subjects {#s4_1}
--------

A total of 269 patients who were diagnosed with glioma at the Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Shaanxi Province (Xi\'an, China) between September 2010 and May 2014 were randomly enrolled in this study. The selection criteria were the following: Han Chinese patient with no kinship; recently diagnosed and histologically confirmed to have glioma; no previous history of other cancers; no prior treatment for glioma or prior treatment with chemotherapy or radiotherapy; underwent regular follow-up; peripheral blood samples available. The protocol of this study was approved by the Ethics Committee of Tangdu Hospital, Fourth Military Medical University, Shaanxi Province (Xi\'an, China), Northwest University, National Engineering Research Center for Miniaturized Detection Systems and the Department of Anesthesiology, Shaanxi Provincial Tumor Hospital, Xi\'an, Shaanxi. All patients gave written informed consent prior to participation in the study.

SNP selection and genotyping {#s4_2}
----------------------------

We selected eight SNPs (rs17172432, rs4947492, rs12718945, rs730437, rs11506105, rs3752651, rs1468727 and rs845552) in EGFR that were found to be associated with glioma risk in European and Han populations \[[@R5]--[@R7]\], and influenced the prognosis of both glioblastoma and other cancer patients \[[@R10], [@R15]\]. Genomic DNAs were extracted through GoldMag-Mini Whole Blood Genomic DNA Purification Kits (GoldMag. Co. Ltd., Xi\'an, China) from peripheral blood samples (5 mL) gathered from glioma patients in strict accordance with the manufacturer\'s protocols. DNA concentrations and purity were evaluated using a spectrophotometer (NanoDrop 2000; Thermo Fisher Scientific, Waltham, MA, USA). We designed polymerase chain reaction (PCR) and extension primers for the SNPs using the Sequenom MassARRAY Assay Design 3.0 software (Sequenom, San Diego, CA, USA). Genotyping of SNPs was designed by using the Sequenom MassARRAY platform with the iPLEX GOLD reagents (Sequenom, San Diego, CA, USA). Finally, we used the Sequenom Typer 4.0 software for data management and analysis.

Clinical data {#s4_3}
-------------

For patients, treatment and survival (overall and progression-free) information were collected from a retrospective review of patient medical records or consultation with treating physicians. A standardized questionnaire was used to collect clinical data, including the date of diagnosis, follow-up date(s), gender, age, exact pathology, WHO grade, histologic type, extent of resection, surgical methods, postoperative radiotherapy and chemotherapy. These data were stored electronically using the EpiData3.02 software, and validation, revision and conversion of assigned values were performed to establish the database of glioma patients used for analysis.

Follow up {#s4_4}
---------

We performed the follow-up to analyze the postoperative survival of glioma patients. Follow-up consisted of telephone interviews, outpatient visits, and written communication with patients or their families. Glioma patients who were alive at the time of the analysis were excluded from the study on the day of the final follow-up. Clinical follow-up regarding the genetic status of glioma patients was performed in single-blind fashion with the end point of cardiac death.

Statistical analyses {#s4_5}
--------------------

All follow-up survey and experimental data were analyzed using SPSS 17.0 (SPSS, Chicago, IL, USA). Survival time was defined as the time between the date of diagnosis and either the date of death (deceased patients) or last contact date (living patients). The OS and PFS were selected as the end evaluation points of this study. OS was measured from the day of surgery until the date of death from any cause or to the date of the last follow-up. PFS was calculated from the date of enrollment to the date of any form of tumor progression or to the last follow-up. The1-year and 3-year survival rates and the MST were determined based on follow-up results. The Kaplan-Meier method was used to estimate PFS and OS. The survival curves were compared using Log-rank tests. Univariate analysis included the following factors: gender, age, WHO grade, extent of resection, radiotherapy, chemotherapy and the eight SNPs. Univariate and multivariable Cox proportional hazard models were used to calculate the crude and adjusted HRs and 95% CIs, respectively. The HRs was adjusted for other factors that could affect glioma outcome such as age, gender, and extent of resection. Two-sided *p* values \< 0.05 were considered statistically significant and were calculated using the Wald test.
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